Hologic Inc (HOLX) 38.98 $HOLX
National Comprehensive Cancer Network (NCCN) Includes Breast Tomosynthesis in Breast Cancer Screening and Diagnosis Practice Guidelines
PR Newswire - Mon Aug 01, 7:01AM CDT
Hologic Inc. (Nasdaq: HOLX) announced today that new guidelines published by the National Comprehensive Cancer Network (NCCN) recommend that physicians consider breast tomosynthesis exams as an option for their patients' annual breast cancer screening.1
HOLX: 38.98 (+0.49)
Upgrade Alert for Hologic (HOLX)
Comtex SmarTrend(R) - Fri Jul 29, 3:08AM CDT
Hologic (NASDAQ:HOLX) was upgraded from Hold to Buy at Evercore ISI today. The stock closed yesterday at $38.27 on volume of 4.5 million shares, below average daily volume of 5.5 million. Hologic, Inc. develops, manufactures, and markets x-ray systems. The Company makes x-ray bone densitometers that measure the precise bone density for use in the diagnosing of metabolic bone diseases such as osteoporosis.
HOLX: 38.98 (+0.49)
Hologic Rises 2.45% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Thu Jul 28, 12:54PM CDT
Hologic (NASDAQ:HOLX) traded in a range yesterday that spanned from a low of $37.62 to a high of $38.71. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $37.29 on volume of 2.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
HOLX: 38.98 (+0.49)
After Yesterday's Rally of 2.45% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu Jul 28, 12:53PM CDT
Hologic (NASDAQ:HOLX) traded in a range yesterday that spanned from a low of $37.62 to a high of $38.71. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $37.29 on volume of 2.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
HOLX: 38.98 (+0.49)
Hologic (HOLX) Beats on Q3 Earnings, Sales; '16 View Up
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 5:29AM CDT
Hologic (HOLX) ended third-quarter fiscal 2016 on a promising note, with both its top and bottom line comfortably exceeding the Zacks Consensus Estimate.
BABY: 39.18 (-0.15), ABMD: 119.50 (+1.53), MASI: 52.93 (-0.04), HOLX: 38.98 (+0.49)
CVS Health (CVS) Q2 Earnings: What's in the Cards?
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 5:43PM CDT
CVS Health Corporation (CVS) is scheduled to report its second-quarter 2016 results before the opening bell on Aug 2.
ZBH: 131.06 (-0.08), CVS: 93.49 (+0.77), BMY: 76.19 (+1.38), HOLX: 38.98 (+0.49)
Hologic Announces Financial Results for Third Quarter of Fiscal 2016
PR Newswire - Wed Jul 27, 3:01PM CDT
Hologic, Inc. (Nasdaq: HOLX) announced today the Company's financial results for the fiscal third quarter ended June 25, 2016. GAAP diluted earnings per share (EPS) of $0.30 increased 200% compared to the prior year period, and non-GAAP diluted EPS of $0.51 increased 18.6%. Revenue of $717.4 million increased 3.4%, or 3.6% in constant currency terms.
HOLX: 38.98 (+0.49)
Research and Markets - Global Diagnostic Imaging Market, 2022 - Key Players are Analogic, GE, Philips, Siemens, Toshiba Medical, Hitachi Medical, Carestream, Hologic, Samsung Medison & Shimadzu
PR Newswire Europe - Wed Jul 27, 8:11AM CDT
DUBLIN, July 27, 2016 /PRNewswire/ --
HOLX: 38.98 (+0.49)
Henry Schein (HSIC) Q2 Earnings: What's in the Cards?
Zacks Equity Research - Zacks Investment Research - Tue Jul 26, 6:56AM CDT
Henry Schein's (HSIC) earnings surpassed the Zacks Consensus Estimate in 3 of the past 4 quarters, with an average beat of 2.03%.
ZBH: 131.06 (-0.08), BMY: 76.19 (+1.38), HSIC: 180.14 (-0.84), HOLX: 38.98 (+0.49)
Look at Jul 27 Medical Instrument Earnings: HOLX, VAR & More
Zacks Equity Research - Zacks Investment Research - Tue Jul 26, 6:51AM CDT
There is some definite good news for investors keen on the Medical sector.
RTIX: 3.10 (-0.15), VAR: 94.84 (+0.10), NVDQ: 10.92 (+0.26), HOLX: 38.98 (+0.49)
Hologic (HOLX) Q3 Earnings: A Surprise in the Cards?
Zacks Equity Research - Zacks Investment Research - Tue Jul 19, 6:31AM CDT
Hologic (HOLX) has a Zacks Rank #2 (Buy) which along with a 0.00 % ESP makes surprise prediction difficult.
AGN: 254.86 (+1.91), LH: 139.63 (+0.07), BMY: 76.19 (+1.38), HOLX: 38.98 (+0.49)
MedTech Tailwinds at a Glance: Which Stocks to Buy?
Zacks Equity Research - Zacks Investment Research - Wed Jul 13, 5:02PM CDT
MedTech Tailwinds at a Glance: Which Stocks to Buy?
ABMD: 119.50 (+1.53), LDRH: 36.98 (-0.02), MDT: 88.06 (+0.43), PAHC: 20.83 (+0.20), MLAB: 114.10 (-1.53), NUVA: 63.29 (+1.09), BSX: 24.43 (+0.15), BABY: 39.18 (-0.15), SNN: 33.18 (-0.11), JNJ: 125.40 (+0.17), DXCM: 92.65 (+0.42), GWPH: 96.11 (+1.79), RMD: 69.85 (+0.97), WOOF: 70.40 (-0.94), ABT: 45.29 (+0.54), VIVO: 19.55 (+0.19), MASI: 52.93 (-0.04), TMO: 159.56 (+0.72), CYH: 12.58 (-0.19), HTWR: 57.96 (+0.02), FEIC: 106.45 (+0.03), ISRG: 693.87 (-1.89), CFMS: 6.92 (-0.05), STE: 71.41 (+0.46), STJ: 83.73 (+0.69), XRAY: 64.23 (+0.19), HOLX: 38.98 (+0.49)
Hologic Set to Possibly Pullback After Yesterday's Rally of 1.84%
Comtex SmarTrend(R) - Thu Jul 07, 1:13PM CDT
Hologic (NASDAQ:HOLX) traded in a range yesterday that spanned from a low of $34.61 to a high of $35.79. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day high of $35.00 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
HOLX: 38.98 (+0.49)
Watch for Hologic to Potentially Pullback After Gaining 1.84% Yesterday
Comtex SmarTrend(R) - Thu Jul 07, 1:11PM CDT
Hologic (NASDAQ:HOLX) traded in a range yesterday that spanned from a low of $34.61 to a high of $35.79. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day high of $35.00 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
HOLX: 38.98 (+0.49)
MEDNAX Stock Up On Accretive Acquisitions & Collaborations
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 9:19AM CDT
MEDNAX Inc. (MD) shares has increased 13.3% in the last three months driven by a plethora of accretive acquisitions.
IBM: 161.45 (+0.83), MD: 68.99 (+0.08), HOLX: 38.98 (+0.49), MCO: 105.27 (-0.74)
Hologic Set to Possibly Pullback After Yesterday's Rally of 3.40%
Comtex SmarTrend(R) - Thu Jun 23, 12:47PM CDT
Hologic (NASDAQ:HOLX) traded in a range yesterday that spanned from a low of $34.17 to a high of $35.33. Yesterday, the shares gained 3.4%, which took the trading range above the 3-day high of $34.77 on volume of 2.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
HOLX: 38.98 (+0.49)
Hologic: FDA Okays Procleix Zika Virus Test under IND Study
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 7:51AM CDT
Hologic's (HOLX) Procleix Zika Virus Test was approved under FDA???s Investigational New Drug (IND) study protocol to detect the presence of Zika virus in donated blood.
ICUI: 117.07 (+0.31), BAX: 48.50 (+0.48), LMAT: 17.89 (+0.69), HOLX: 38.98 (+0.49)
Hologic's Zika Virus Test Gets FDA Nod for Emergency Use
Zacks Equity Research - Zacks Investment Research - Mon Jun 20, 7:58AM CDT
Hologic (HOLX) will run the Aptima Zika virus test on its market leading Panther platform, which substantially reduces hands-on time for laboratories and the potential for manual errors.
ICUI: 117.07 (+0.31), BAX: 48.50 (+0.48), LMAT: 17.89 (+0.69), HOLX: 38.98 (+0.49)
FDA Approves Use of the Procleix Zika Virus Assay from Hologic and Grifols to Screen the U.S. Blood Supply Under an IND Study Protocol
PR Newswire - Mon Jun 20, 7:00AM CDT
Hologic, Inc. (NASDAQ: HOLX) and Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS) - market-leading partners committed to blood safety - announced today that the U.S. Food and Drug Administration (FDA) has approved use of the Procleix Zika virus blood screening assay on the Procleix Panther system under the agency's Investigational New Drug (IND) study protocol.
GRFS: 16.76 (-0.18), HOLX: 38.98 (+0.49)
National Comprehensive Cancer Network (NCCN) Includes Breast Tomosynthesis in Breast Cancer Screening and Diagnosis Practice Guidelines
PR Newswire - Mon Aug 01, 7:01AM CDT
Hologic Inc. (Nasdaq: HOLX) announced today that new guidelines published by the National Comprehensive Cancer Network (NCCN) recommend that physicians consider breast tomosynthesis exams as an option for their patients' annual breast cancer screening.1
HOLX: 38.98 (+0.49)
Upgrade Alert for Hologic (HOLX)
Comtex SmarTrend(R) - Fri Jul 29, 3:08AM CDT
Hologic (NASDAQ:HOLX) was upgraded from Hold to Buy at Evercore ISI today. The stock closed yesterday at $38.27 on volume of 4.5 million shares, below average daily volume of 5.5 million. Hologic, Inc. develops, manufactures, and markets x-ray systems. The Company makes x-ray bone densitometers that measure the precise bone density for use in the diagnosing of metabolic bone diseases such as osteoporosis.
HOLX: 38.98 (+0.49)
Hologic Rises 2.45% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Thu Jul 28, 12:54PM CDT
Hologic (NASDAQ:HOLX) traded in a range yesterday that spanned from a low of $37.62 to a high of $38.71. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $37.29 on volume of 2.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
HOLX: 38.98 (+0.49)
After Yesterday's Rally of 2.45% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu Jul 28, 12:53PM CDT
Hologic (NASDAQ:HOLX) traded in a range yesterday that spanned from a low of $37.62 to a high of $38.71. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $37.29 on volume of 2.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
HOLX: 38.98 (+0.49)
Hologic (HOLX) Beats on Q3 Earnings, Sales; '16 View Up
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 5:29AM CDT
Hologic (HOLX) ended third-quarter fiscal 2016 on a promising note, with both its top and bottom line comfortably exceeding the Zacks Consensus Estimate.
BABY: 39.18 (-0.15), ABMD: 119.50 (+1.53), MASI: 52.93 (-0.04), HOLX: 38.98 (+0.49)
CVS Health (CVS) Q2 Earnings: What's in the Cards?
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 5:43PM CDT
CVS Health Corporation (CVS) is scheduled to report its second-quarter 2016 results before the opening bell on Aug 2.
ZBH: 131.06 (-0.08), CVS: 93.49 (+0.77), BMY: 76.19 (+1.38), HOLX: 38.98 (+0.49)
Hologic Announces Financial Results for Third Quarter of Fiscal 2016
PR Newswire - Wed Jul 27, 3:01PM CDT
Hologic, Inc. (Nasdaq: HOLX) announced today the Company's financial results for the fiscal third quarter ended June 25, 2016. GAAP diluted earnings per share (EPS) of $0.30 increased 200% compared to the prior year period, and non-GAAP diluted EPS of $0.51 increased 18.6%. Revenue of $717.4 million increased 3.4%, or 3.6% in constant currency terms.
HOLX: 38.98 (+0.49)
Research and Markets - Global Diagnostic Imaging Market, 2022 - Key Players are Analogic, GE, Philips, Siemens, Toshiba Medical, Hitachi Medical, Carestream, Hologic, Samsung Medison & Shimadzu
PR Newswire Europe - Wed Jul 27, 8:11AM CDT
DUBLIN, July 27, 2016 /PRNewswire/ --
HOLX: 38.98 (+0.49)
Henry Schein (HSIC) Q2 Earnings: What's in the Cards?
Zacks Equity Research - Zacks Investment Research - Tue Jul 26, 6:56AM CDT
Henry Schein's (HSIC) earnings surpassed the Zacks Consensus Estimate in 3 of the past 4 quarters, with an average beat of 2.03%.
ZBH: 131.06 (-0.08), BMY: 76.19 (+1.38), HSIC: 180.14 (-0.84), HOLX: 38.98 (+0.49)
Look at Jul 27 Medical Instrument Earnings: HOLX, VAR & More
Zacks Equity Research - Zacks Investment Research - Tue Jul 26, 6:51AM CDT
There is some definite good news for investors keen on the Medical sector.
RTIX: 3.10 (-0.15), VAR: 94.84 (+0.10), NVDQ: 10.92 (+0.26), HOLX: 38.98 (+0.49)
Hologic (HOLX) Q3 Earnings: A Surprise in the Cards?
Zacks Equity Research - Zacks Investment Research - Tue Jul 19, 6:31AM CDT
Hologic (HOLX) has a Zacks Rank #2 (Buy) which along with a 0.00 % ESP makes surprise prediction difficult.
AGN: 254.86 (+1.91), LH: 139.63 (+0.07), BMY: 76.19 (+1.38), HOLX: 38.98 (+0.49)
MedTech Tailwinds at a Glance: Which Stocks to Buy?
Zacks Equity Research - Zacks Investment Research - Wed Jul 13, 5:02PM CDT
MedTech Tailwinds at a Glance: Which Stocks to Buy?
ABMD: 119.50 (+1.53), LDRH: 36.98 (-0.02), MDT: 88.06 (+0.43), PAHC: 20.83 (+0.20), MLAB: 114.10 (-1.53), NUVA: 63.29 (+1.09), BSX: 24.43 (+0.15), BABY: 39.18 (-0.15), SNN: 33.18 (-0.11), JNJ: 125.40 (+0.17), DXCM: 92.65 (+0.42), GWPH: 96.11 (+1.79), RMD: 69.85 (+0.97), WOOF: 70.40 (-0.94), ABT: 45.29 (+0.54), VIVO: 19.55 (+0.19), MASI: 52.93 (-0.04), TMO: 159.56 (+0.72), CYH: 12.58 (-0.19), HTWR: 57.96 (+0.02), FEIC: 106.45 (+0.03), ISRG: 693.87 (-1.89), CFMS: 6.92 (-0.05), STE: 71.41 (+0.46), STJ: 83.73 (+0.69), XRAY: 64.23 (+0.19), HOLX: 38.98 (+0.49)
Hologic Set to Possibly Pullback After Yesterday's Rally of 1.84%
Comtex SmarTrend(R) - Thu Jul 07, 1:13PM CDT
Hologic (NASDAQ:HOLX) traded in a range yesterday that spanned from a low of $34.61 to a high of $35.79. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day high of $35.00 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
HOLX: 38.98 (+0.49)
Watch for Hologic to Potentially Pullback After Gaining 1.84% Yesterday
Comtex SmarTrend(R) - Thu Jul 07, 1:11PM CDT
Hologic (NASDAQ:HOLX) traded in a range yesterday that spanned from a low of $34.61 to a high of $35.79. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day high of $35.00 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
HOLX: 38.98 (+0.49)
MEDNAX Stock Up On Accretive Acquisitions & Collaborations
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 9:19AM CDT
MEDNAX Inc. (MD) shares has increased 13.3% in the last three months driven by a plethora of accretive acquisitions.
IBM: 161.45 (+0.83), MD: 68.99 (+0.08), HOLX: 38.98 (+0.49), MCO: 105.27 (-0.74)
Hologic Set to Possibly Pullback After Yesterday's Rally of 3.40%
Comtex SmarTrend(R) - Thu Jun 23, 12:47PM CDT
Hologic (NASDAQ:HOLX) traded in a range yesterday that spanned from a low of $34.17 to a high of $35.33. Yesterday, the shares gained 3.4%, which took the trading range above the 3-day high of $34.77 on volume of 2.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
HOLX: 38.98 (+0.49)
Hologic: FDA Okays Procleix Zika Virus Test under IND Study
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 7:51AM CDT
Hologic's (HOLX) Procleix Zika Virus Test was approved under FDA???s Investigational New Drug (IND) study protocol to detect the presence of Zika virus in donated blood.
ICUI: 117.07 (+0.31), BAX: 48.50 (+0.48), LMAT: 17.89 (+0.69), HOLX: 38.98 (+0.49)
Hologic's Zika Virus Test Gets FDA Nod for Emergency Use
Zacks Equity Research - Zacks Investment Research - Mon Jun 20, 7:58AM CDT
Hologic (HOLX) will run the Aptima Zika virus test on its market leading Panther platform, which substantially reduces hands-on time for laboratories and the potential for manual errors.
ICUI: 117.07 (+0.31), BAX: 48.50 (+0.48), LMAT: 17.89 (+0.69), HOLX: 38.98 (+0.49)
FDA Approves Use of the Procleix Zika Virus Assay from Hologic and Grifols to Screen the U.S. Blood Supply Under an IND Study Protocol
PR Newswire - Mon Jun 20, 7:00AM CDT
Hologic, Inc. (NASDAQ: HOLX) and Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS) - market-leading partners committed to blood safety - announced today that the U.S. Food and Drug Administration (FDA) has approved use of the Procleix Zika virus blood screening assay on the Procleix Panther system under the agency's Investigational New Drug (IND) study protocol.
GRFS: 16.76 (-0.18), HOLX: 38.98 (+0.49)
